8-KItem 2.02 · Results of OperationsItem 7.01 · Reg FD DisclosureItem 9.01 · Financial Statements
On Feb 13, 2026 Insulet's Board approved a $350M increase to the prior $125M share repurchase…
Filed with the SEC on · Summarized by InvestorsBot
On Feb 13, 2026 Insulet's Board approved a $350M increase to the prior $125M share repurchase authorization, extending the program through 12/31/2027 — total authorization now $475M. $PODD 📈 #Buybacks #MedTech
As of Feb 16, 2026 Insulet has repurchased $60M under the program; $415M remains available for buybacks. $PODD 🔁 #Buybacks #Investing
Company expects to fund repurchases with existing cash and plans to allocate ~ $300M to buybacks in Q1 2026. Program is discretionary and may be modified or suspended. $PODD 💵 #Buybacks #MedTech